

Solitary Synchronous Pancreatic Metastasis from Esophageal Squamous Cell Carcinoma: A Rare Case Report

Shahram Ahmadi Somaghian^{**}, MSc, Sepideh Mirzaei^{**}, MD, Asghar Aaliehpour^{***}, MD, Yahya Baharvand Iran Nia^{****}, MD

**Department of Hematology and Oncology, Lorestan University of Medical Sciences, Khorramabad, Iran*

***Department of Radiotherapy, Lorestan University of Medical Sciences, Khorramabad, Iran*

****Department of Pathology, Lorestan University of Medical Sciences, Khorramabad, Iran*

*****Department of Internal Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran*

Please cite this article as:
Ahmadi Somaghian S, Mirzaei S, Aaliehpour A, Baharvand Iran Nia Y. Solitary synchronous pancreatic metastasis from esophageal squamous cell carcinoma: A rare case report. Middle East J Cancer. 2021;12(2): 310-4. doi: 10.30476/mejc.2020.86963.1379.

Abstract

Pancreas is an organ that is hardly affected by metastasis from other primary cancers; also, pancreatic metastasis from esophageal squamous cell carcinoma (ESCC) is an extremely infrequent entity. Metastatic esophageal cancer has a poor prognosis and the five-year survival rate is less than 5%. Here, we described a rare case of a 78-year-old woman presented with abdominal bloating, intermittent mild nausea, and loss of appetite and weight. Esophagogastroduodenoscopy revealed ESCC in the upper part of esophagus. A mass lesion between the head and body of pancreas was detected during metastatic work-up. Endoscopic ultrasound-guided fine needle aspiration was performed, morphologic features and immunohistochemistry confirmed metastatic squamous cell carcinoma from esophagus. Definitive chemoradiotherapy with curative intent was done on both oesophageal and pancreatic lesion. Interestingly, after nine months of treatment, the patient had no issues either in esophagus or in abdomen. In conclusion, local therapy could be considered as one of the best choices to improve the overall survival in ESCC with single metastasis to pancreas.

Keywords: Definitive chemoradiotherapy, Esophagus, Pancreas neoplasm, Solitary metastasis, Radiotherapy

Corresponding Author:

Yahya Baharvand Iran Nia, MD
Department of Internal Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
Tel: +98 66-33336143
Fax: 066-33336151
Email: y.b.i31333@gmail.com

Introduction

Esophageal cancer is a poor prognosis malignancy often diagnosed at an advanced stage due

to inability to detect early symptoms.¹ According to the data from GLOBOCAN database (2018), esophageal cancer is the ninth most

prevalent malignancy and the sixth most common cause of cancer-related mortality worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common type (90%) of esophageal malignancy in Asian countries; however, in western countries such as the United States, esophageal adenocarcinoma accounts for more than 60% of all esophageal cancers.² Smoking and alcohol consumption are among the major risk factors associated with esophageal cancer; meanwhile, Barrett's esophagus with intestinal metaplasia, obesity, and smoking are the risk factors for adenocarcinoma.^{3, 4}

Case presentation

A 78-year-old woman presented with a five-month history of abdominal bloating, intermittent mild nausea, and loss of appetite and weight (12 kg). There was no family history for malignancy and hereditary disease. She had no history of smoking or alcohol consumption and her body mass index (BMI) was 20. The subject reported a 20-year history of diabetes mellitus with regular follow-up and the cardiac resynchronization therapy (CRT) implanted due to threatening tachyarrhythmia for 10 years. No abnormalities were detected in initial abdominopelvic ultrasonography and physical examination. Esophagogastroduodenoscopy revealed a polypoid infiltrative lesion without oozing in




Figure 1. Upper endoscopy shows a lesion with an irregular nodular surface 22 cm from the incisors.

20cm from incisor (Figure 1); multiple biopsies were taken and the histopathology was consistent with a well-differentiated squamous cell carcinoma (SCC) (Figure 2). Further evaluation and metastatic work-up with abdominal computed tomography (CT) demonstrated a mass lesion measuring 39×31 mm between the body and head of the pancreas (Figure 3). Core needle biopsy (CNB) could not be performed because the mass was fragile; therefore, she underwent endoscopic ultrasound (EUS) for fine needle aspiration (FNA); multiple slides and two bottles of cell block were further taken (Figure 4). The pathology




Figure 2. Histological examination of esophagus (A) and pancreas (B), suggests well-differentiated squamous cell carcinoma (H & E stain, ×400).

examination showed that the tumor was metastatic SCC with morphologic features similar to the previous ESCC. Immunohistochemistry (IHC) was positive for P65 and CK5.

Liver function tests and cell blood count were within the normal limit. The patient underwent CRT for pancreas mass (5040 cGy in 28 fractions with capecitabine 1.5 gr daily). Symptoms were reduced and she was subjected to CRT to esophagus (4500 cGy in 25 fraction with capecitabine 1.5gr daily) followed by brachytherapy (10 Gy in two fraction). Nine months after treatment, the pancreatic lesion size decreased from 42×36 mm to 26×26 mm; the patient had no problem swallowing and upper-endoscopy revealed no sign of recurrence in esophagus.

Discussion

More than 50% of patients have either unresectable cancer or metastases to distant organs at preliminary diagnosis.⁵ These patients have a dismal prognosis, and the median overall survival (OS) is six and five months for patients with a solitary site of distant metastasis (DM) and several sites of DM, respectively.⁶

It has been reported that esophageal cancer has a special propensity for unexpected specific site metastasis; this has been attributed to the




Figure 3. Abdominal axial CT-scan revealing a contrast-enhanced pancreatic metastasis from ESCC with encasement of celiac artery. CT: Computed tomography; ESCC: Esophageal squamous cell carcinoma

particular anatomical esophageal features considered as having a key role in elucidating esophageal cancer with distinctive and extremely aggressive nature.⁷

In general, 58.6% of patients with de novo stage 4 esophageal cancer have DM to a single organ. Esophageal cancer most commonly spreads to the liver (33.4%), followed by distant (non-regional) lymph nodes (26.6%), lung (20.5%), bone (15.7%), and brain (3.8%).⁶ Most malignant tumors in the pancreas are primary, only 20% are metastatic lesions, SCC, small cell carcinoma,




Figure 4. Endoscopic ultrasound and elastography shows a 42 mm to 36 mm hypoechoic lesion in pancreatic genu with invasion to port and superior mesenteric artery (SMA).

and acinar cell carcinoma, and the others are adenocarcinomas.^{8,9} Solitary pancreatic metastases from non-pancreatic primary cancers are highly uncommon, roughly causing only 2% of all pancreatic tumors.¹⁰

To the best of our knowledge, only two cases of solitary synchronous pancreatic metastasis from ESCC have been reported in English literature.^{11,12} We reported a case of isolated synchronous pancreatic metastasis from ESCC diagnosed during preoperative metastatic work-up for the treatment of primary esophageal cancer.

In our case, it was difficult to distinguish a synchronous pancreatic carcinoma from a solitary pancreatic metastasis from primary ESCC. Given its rarity, SCC of the pancreas is supposed to be the result of metastasis from other primary sites until confirmed otherwise.¹³ The final diagnosis of metastatic ESCC to the pancreas was confirmed only after conducting FNA through EUS, followed by pathology and IHC examination.

Overall, local therapy is not routinely suggested for metastatic cancer, ESCC or otherwise; however, several reports have indicated that the resection of pancreatic metastatic lesions in patients with diverse primary cancer increases disease-free interval and enhances patients' OS.^{14,15} The effectiveness of pancreatic resection is mostly associated with the biology of the primary cancer metastasizing to the pancreas. It has been suggested that pancreatic metastasectomy can be a useful treatment for solitary pancreatic metastasis of ESCC without the possibility of spreading to another site.¹⁵

In such cases, local therapy seems logical for treating and enhancing the OS of patients. In our case, the pancreatic lesion was unresectable due to the encasement of superior mesenteric artery. Thus, definitive chemo-radiotherapy with curative intent was performed as one of the best alternatives for esophageal and pancreatic lesion.

Conclusion

In conclusion, we reported this case because solitary pancreatic metastasis of ESCC is very rare, and only a handful of cases have been

reported to date. It is important to determine whether local therapy is an appropriate treatment regimen for isolated pancreatic metastasis from ESCC; due to its rarity, more research is required to confirm the usefulness of local therapy in these cases.

Informed Consent

Written informed consent for publishing the case report was signed by the patient.

Conflict of Interest

None declared.

References

1. Triboulet JP, Mariette C. Cancer de l'oesophage: quoi de neuf dans la prise en charge depuis 10 ans? Oesophageal cancer: what's new during the last 10 years? [Article in French] *Bull Cancer*. 2008;95(4):425-31. doi:10.1684/bdc.2008.0626.
2. Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? *Cancer Epidemiol*. 2016;41:88-95. doi:10.1016/j.canep.2016.01.013.
3. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC; Australian Cancer Study. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. *Gastroenterology*. 2009;136(4):1215-e2. doi:10.1053/j.gastro.2008.12.052.
4. Zhang Y. Epidemiology of esophageal cancer. *World J Gastroenterol*. 2013;19(34):5598-606. doi:10.3748/wjg.v19.i34.5598.
5. Enzinger PC, Mayer RJ. Esophageal cancer. *N Engl J Med*. 2003;349(23):2241-52. doi:10.1056/NEJMra035010.
6. Wu SG, Zhang WW, He ZY, Sun JY, Chen YX, Guo L. Sites of metastasis and overall survival in esophageal cancer: a population-based study. *Cancer Manag Res*. 2017;9:781-8. doi:10.2147/CMAR.S150350.
7. Shaheen O, Ghibour A, Alsaid B. Esophageal cancer metastases to unexpected sites: A systematic review. *Gastroenterol Res Pract*. 2017;2017:1657310. doi:10.1155/2017/1657310.
8. Mulkeen AL, Yoo PS, Cha C. Less common neoplasms of the pancreas. *World J Gastroenterol*. 2006;12(20):3180-5. doi:10.3748/wjg.v12.i20.3180.
9. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. *HPB (Oxford)*. 2008;10(1):58-62. doi:10.1080/13651820701883148.
10. Rumancik WM, Megibow AJ, Bosniak MA, Hilton S. Metastatic disease to the pancreas: evaluation by computed tomography. *J Comput Assist Tomogr*.

- 1984;8(5):829-34. doi:10.1097/00004728-198410000-00003.
11. Sawada T, Adachi Y, Noda M, Akino K, Kikuchi T, Mita H, et al. Hepatic portal venous gas in pancreatic solitary metastasis from an esophageal squamous cell carcinoma. *Hepatobiliary Pancreat Dis Int.* 2013;12(1):103-5. doi: 10.1016/s1499-3872(13)60015-6.
 12. Park C, Jang JY, Kim YH, Hwang EJ, Na KY, Kim KY, et al. A case of esophageal squamous cell carcinoma with pancreatic metastasis. *Clin Endosc.* 2013;46(2):197-200. doi:10.5946/ce.2013.46.2.197.
 13. Bixler HA, Castro MJ, Stewart J 3rd. Cytologic differentiation of squamous elements in the pancreas. *Diagn Cytopathol.* 2011;39(7):536-40. doi:10.1002/dc.21479.
 14. Hiotis SP, Klimstra DS, Conlon KC, Brennan MF. Results after pancreatic resection for metastatic lesions. *Ann Surg Oncol.* 2002;9(7):675-9. doi:10.1007/BF02574484.
 15. Sperti C, Moletta L, Patanè G. Metastatic tumors to the pancreas: The role of surgery. *World J Gastrointest Oncol.* 2014;6(10):381-92. doi:10.4251/wjgo.v6.i10.381.